一分钟看懂
这是一项关于乳腺癌的I 期研究，登记的药物或干预包括[68Ga]Ga-NeoB；[177Lu]Lu-NeoB；Ribociclib；Fulvestrant；Goserelin，当前状态为研究进行中，已停止招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
[68Ga]Ga-NeoB；[177Lu]Lu-NeoB；Ribociclib；Fulvestrant；Goserelin · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Novartis Investigative Site · 上海
公开的入选条件
- Key Inclusion criteria:
- * Adult female or male \>= 18 years of age at the time of informed consent
- * Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive with ER \>10% (regardless of progesterone receptor (PgR) expression) breast cancer by local laboratory testing (based on the most recently analyzed tissue sample)
- * HER2 negative breast cancer defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (e.g. fluorescence in situ hybridization (FISH), chromogenic in situ hybridiza
- * Participant has advanced (loco regionally recurrent not amenable to curative therapy (e.g. surgery and/or radiotherapy) or metastatic) breast cancer
- Participants may be:
- 1. relapsed with documented evidence of relapse on or within 12 months from completion of (neo)adjuvant endocrine therapy (+/- CDK4/6 inhibitor) with no treatment for advanced disease OR
- 2. relapsed with documented evidence of relapse more than 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression after one line of endocrine therapy (except fulvestrant) (+/- CDK4/6
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05870579；登记信息更新于 2026-09-11。